Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) EV/FCF
As of 16 October 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a EV/FCF of 31.4×. Over the past ten years it has ranged from −440× (August 2016) to 347× (November 2016); the current reading is higher than 65% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 34.4× | — |
| FY2024 | −100× | — |
| FY2023 | 28.6× | 77.46% |
| FY2022 | 16.1× | (22.25%) |
| FY2021 | 20.7× | 11.54% |
| FY2020 | 18.6× | (47.90%) |
| FY2019 | 35.6× | 5.05% |
| FY2018 | 33.9× | (31.37%) |
| FY2017 | 49.4× | (49.76%) |
| FY2016 | 98.4× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 31.2× | 8.69% |
| Mar 2026 | 28.7× | (16.35%) |
| Dec 2025 | 34.4× | 21.68% |
| Sep 2025 | 28.2× | (8.77%) |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MRNA Moderna, Inc. compare | −66.1× |
| RVMD Revolution Medicines, Inc. compare | −28.1× |
| ROIV Roivant Sciences Ltd. compare | −25.1× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 21.5× |
| RPRX Royalty Pharma PLC compare | 27.0× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 28.5× |
| VRTX Vertex Pharmaceuticals Incorporated | 31.4× |
| ARGX argenex SE compare | 34.4× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 35.0× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement